Profits For Czech Republic's Leciva
Leciva Praha, a producer of pharmaceuticals based in the Czech Republic capital Prague, recorded a 379 million koruna ($13.9 million) profit on turnover of 3.85 billion koruna ($149.0 million), according to preliminary figures reported by the CTK news agency's Business News. The company's 1995 business plan envisages a profit of 480 million koruna and sales of 4.4 billion koruna.
Leciva produces 180 preparations for 250 medicines, mostly antibiotics, chemotherapy agents, diabetes drugs, analgesics and vitamins. It cooperates with companies such as Roussel Uclaf, Ugmetin and SmithKline Beecham.
Some 72% of its production is sold on the Czech market, 20% is exported to Slovakia and 8% is exported to the CIS and eastern Europe. The company's investment in improving products in 1994 totalled 267 million koruna, and this is likely to reach 300 million koruna in 1995, the report notes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze